Ronan Foley - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Member, McMaster Centre for Transfusion Research (MCTR), Faculty of Health Sciences
Professor, Oncology, Faculty of Health Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

chapters
- Haemopoietic Stem Cell Processing and Storage. 519-530. 2022
- Haemopoietic Stem Cell Processing and Storage. 455-465. 2017
- Haemopoietic Stem Cell Processing and Storage. 443-454. 2013
- Dendritic Cell-Based Cancer Vaccines: Practical Considerations. 107-126. 2011
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Conclusion. 175-184. 2010
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Introduction. 1-18. 2010
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Preface. XI-+. 2010
- Holy Wells: The Faith Cure. 19-47. 2010
- Sea Bathing: The Thalassic Cure. 111-142. 2010
- Spa Towns: The Rest Cure. 49-78. 2010
- The Modern Spa: The Relaxation Cure. 143-173. 2010
- Turkish Baths and Sweat-houses: The Sweating Cure. 79-110. 2010
conferences
- Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Blood. 3496-3496. 2023
- Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. Blood. 3497-3497. 2023
- Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 1584-1587. 2022
- Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 429-429. 2021
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Bone Marrow Transplantation. 48-51. 2020
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 6-7. 2020
- Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncology Research and Treatment. 62-63. 2020
- Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial. Oncology Research and Treatment. 58-58. 2020
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. Blood. 2883-2883. 2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Blood. 4103-4103. 2019
- Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). Blood. 242-242. 2019
- Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. Blood. 875-875. 2019
- Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients. Clinical Lymphoma, Myeloma and Leukemia. S251-S252. 2019
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. Transplantation and Cellular Therapy. S20-S21. 2019
- Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study. Transplantation and Cellular Therapy. S181-S182. 2019
- FACTs Fabry gene therapy clinical trial: Two-year data. Molecular Genetics and Metabolism. S99-S99. 2019
- Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL). Oncology Research and Treatment. 238-238. 2019
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. Blood. 1684-1684. 2018
- Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. Bone Marrow Transplantation. 1263-1269. 2018
- Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: Follow up of a CBMTG randomized trial. Bone Marrow Transplantation. 395-396. 2018
- Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Bone Marrow Transplantation. 177-178. 2018
- REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT. Bone Marrow Transplantation. 444-446. 2018
- Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Cancer Research. CT110-CT110. 2018
- Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. Journal of Clinical Oncology. 3044-3044. 2018
- Evaluation of Subcutaneous Rituximab Administration Impacts on Canadian Systemic Therapy Suites. Value in Health. S250-S250. 2018
- Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3). Transplantation and Cellular Therapy. S208-S208. 2018
- An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncology Research and Treatment. 36-37. 2018
- Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2017
- Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2017
- Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 2017
- Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 1679-1682. 2017
- Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis. Clinical Lymphoma, Myeloma and Leukemia. S373-S374. 2017
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - AN INTERIM ANALYSIS. Clinical Lymphoma, Myeloma and Leukemia. 2017
- Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. Blood. 1226-1226. 2016
- Phase II Clinical Trial of Allodepleted T Cell Immunotherapy (ATIR101) Post-Transplant Results in Decreased Transplant-Related Mortality and Improved Survival in Acute Leukemia Patients Undergoing T-Depleted Haploidentical Stem Cell Transplantation. Cytotherapy. S15-S15. 2016
- Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. Transplantation and Cellular Therapy. S37-S38. 2016
- Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL. Bone Marrow Transplantation. S27-S28. 2016
- Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange. Blood. 2261-2261. 2015
- Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen. Blood. 4391-4391. 2015
- A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or Refractory TTP. Blood. 4191-4191. 2014
- Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. Blood. 2014
- Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. Blood. 38-38. 2014
- Towards a clinical trial of lentivirus-mediated gene therapy for Fabry disease: In vitro patient cell mobilization and transduction outcomes. Clinical Biochemistry. 151-151. 2014
- Pre-Clinical Patient Cell Mobilizations and Transduction Outcomes in Preparation for a Clinical Trial Application of Lentivirus-Mediated Gene Therapy for Fabry Disease. Molecular Therapy. S140-S140. 2014
- Immunotherapy with donor lymphocytes depleted of anti-host reactive cells results in safe and efficacious haploidentical HSCT: interim results from a phase II trial in patients with hematologic malignancies. Cytotherapy. S27-S27. 2014
- CD34 CELL DOSE IS CORRELATED WITH HEMATOLOGIC RECOVERY BUT NOT CHRONIC GVHD: RESULTS OF THE CBMTG TRIAL COMPARING G-CSF-MOBILIZED PERIPHERAL BLOOD(G-PB) VS G-CSF STIMULATED BONE MARROW(G-BM) IN SIBLING ALLOGRAFTS FOR HEMATOLOGIC MALIGNANCIES. Bone Marrow Transplantation. S55-S56. 2014
- DONOR B CELLS POPULATIONS, IFNG-PRODUCING T CELLS, AND CD56BRIGHT NK CELLS CORRELATE WITH DEVELOPMENT OF CHRONIC GVHD IN G-CSF STIMULATED SIBLING DONOR PERIPHERAL BLOOD AND BONE MARROW: RESULTS FROM THE CANADIAN BMT GROUP 0601 RANDOMIZED, PHASE III TRIAL. Bone Marrow Transplantation. S299-S299. 2014
- SELECTIVE PHOTODEPLETION OF RECIPIENT-ALLOREACTIVE T-CELLS ENABLES SAFE AND EFFICACIOUS HAPLOIDENTICAL HSCT: INTERIM RESULTS FROM A PHASE II TRIAL IN PATIENTS WITH AML, ALL, AND MDS. Bone Marrow Transplantation. S221-S221. 2014
- Vaccination with autologous dendritic cells pulsed with a MUC1 glycopeptide: a phase I/II study in castrate resistant non-metastatic prostate cancer patients. Cytotherapy. S39-S39. 2013
- Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring. Molecular Genetics and Metabolism. S21-S21. 2013
- Higher Proportions of IFNg-Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial. Blood. 1944-1944. 2012
- Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients. Cancer Research. A16-A16. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 917-917. 2011
- AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG). Annals of Oncology. 115-115. 2011
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy. Blood. 566-566. 2009
- Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease.. Blood. 1385-1386. 2009
- Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease. Blood. 1388-1388. 2009
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- Synthesis and catalytic activity of Bis-diimidazolylidine complexes of nickel. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2009
- A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International, Supplement. S55-S58. 2009
- INOR 390-Iminoisoindoline-ligated palladacycles: Synthesis and catalytic activity for C-C bond forming reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- INOR 648-Synthesis of nonsymmetrically substituted chelating bis-NHC Palladium(II) complexes for C-C and C-X coupling reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- INOR 764-Investigations into homogeneous copper(II) systems for ethylene polymerization. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- Outcomes of reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma - national review of the Canadian experience by the Canadian Blood and Marrow Transplant Group. Bone Marrow Transplantation. S250-S250. 2008
- A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood. 908-908. 2007
- ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.. Blood. 2895-2895. 2007
- INOR 48-Palladacycles vs. chelating N-heterocyclic carbene complexes of nickel as catalysts for C-C bond forming reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2007
- Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood. 3720-3720. 2006
- 316. Production of Adenoviral Vectors in an Academic cGMP Facility. Molecular Therapy. S121-S121. 2006
- The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review.. Blood. 2192-2192. 2004
- Canadian pilot trial of haploidentical donor transplantation.. Blood Cells, Molecules, and Diseases. 181-182. 2004
- Canadian pilot trial of haplo-identical donor transplantation. Transplantation and Cellular Therapy. 38-38. 2004
- Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells.. Blood. 439A-439A. 2003
- The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation. Blood. 983A-983A. 2003
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma. 39-48. 2003
- Reactivity of vinyl chloride with single-site olefin polymerization catalysts.. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. A66-A66. 2002
- Canadian bone marrow transplant group (CBMTG) will use modified perugia protocol for multi-centre pilot study of haplo-identical transplantation. Leukemia. 416-416. 2002
- The combined effect of all trans retinoic acid and the glucocorticoid, budesonide, on eosinophil differentiation from cord blood-derived CD34+ progenitor cells in vitro. Journal of Allergy and Clinical Immunology. S166-S166. 2002
- Bone marrow derived dendritic cell vaccination of spontaneous canine melanoma using human gp100 antigen. Clinical and immunological findings.. Blood. 698A-698A. 2001
- Patients with severe sepsis vary markedly in their ability to generate activated protein C.. Blood. 445A-445A. 2001
- Reactions of vinyl chloride with single-site ethylene polymerization catalysts.. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. U612-U612. 2001
- The effect of the glucocorticoid, budesonide, on eosinophil differentiation from bone marrow CD34(+) progenitors in vitro. Journal of Allergy and Clinical Immunology. S176-S176. 2001
- Upregulation of eotaxin receptor, CCR3, on bone marrow CD34+progenitor cells following allergen-inhalation challenge in asthmatic subjects: A mechanism of progenitor cell egress from the bone marrow during allergic inflammation. Journal of Allergy and Clinical Immunology. S324-S324. 2001
- A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma.. Blood. 846A-846A. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?. Blood. 132A-132A. 2000
- Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes.. Blood. 335B-335B. 2000
- 227 Glucocorticoid enhancement of IL-5-induced bone marrow eosinophil progenitor colony formation in vitro. Journal of Allergy and Clinical Immunology. S74-S74. 2000
- 521 Increased numbers of eosinophil progenitor cells (CD34+IL5R?+) in the bone marrow of atopic asthmatic subjects. Journal of Allergy and Clinical Immunology. S172-S172. 2000
- Adenoviral-based gene transfer in a murine model of chronic lymphocytic leukemia.. Blood. 314A-314A. 1999
- Optimum timing of apheresis following rHuGCSF and rmetHuSCF in multiple myeloma: A temporal analysis of CD34 absolute counts and subsets.. Blood. 554A-554A. 1999
- The preferences of traditional quality of life domains are similar in older versus younger patients with non-Hodgkin's lymphoma.. Blood. 185A-185A. 1999
- CD34+ t(15;17) APL represents a distinct subgroup associated with CD2+, bcr3 isoform, microgranular morphology, a high white count and a poor prognosis.. Blood. 604A-604A. 1998
- Loss of CD34(+)/CD38(-) cells during ex vivo expansion of purified CD34(+) stem cells using adenoviral-based gene transfer of stem cell factor to bone marrow stromal cells.. Blood. 151A-151A. 1998
- The entity of CD34+ t (15; 17) acute promyelocytic leukemia. British Journal of Haematology. 100-100. 1998
- First 100 donors in the Canadian bone marrow transplant group trial comparing peripheral blood (PB) and bone marrow (BM) in allogeneic transplant.. Bone Marrow Transplantation. S36-S36. 1998
- Adenoviral-based gene transfer of two forms of stem cell factor to human bone marrow stromal cells.. Blood. 4609-4609. 1997
- Intramarrow administration of an adenoviral vector expressing canine GM-CSF to alleviate neutropenia in dogs treated with chemotherapy.. Blood. 1062-1062. 1997
- Isolation and characterization of cultured human dendritic cells: A potential target for adenoviral-based gene transfer of tumour peptides.. Blood. 4636-4636. 1997
- Inhaled allergen-induced changes in bone marrow eosinophil/basophil progenitors in mild asthmatic subjects.. Journal of Allergy and Clinical Immunology. 1485-1485. 1997
- Monitoring interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation: A marker of acute graft-versus-host disease. Blood. 1675-1675. 1996
- Adenovirus‐Vector‐Mediated Cytokine Gene Transfer to Lung Tissue^a. Annals of the New York Academy of Sciences. 235-244. 1996
- ADENOVIRUS VECTOR CYTOKINE GENE-TRANSFER TO LUNG-TISSUE. Journal of Cellular Biochemistry. 377-377. 1995
- ADENOVIRUS VECTOR CYTOKINE GENE-TRANSFER TO LUNG-TISSUE. The FASEB Journal. A858-A858. 1995
- EFFECTIVE CYTOKINE GENE-TRANSFER TO BONE-MARROW STROMAL CELLS USING ADENOVIRAL VECTORS. Journal of Cellular Biochemistry. 406-406. 1995
- EFFECTIVE CYTOKINE GENE-TRANSFER IN HUMAN LONG-TERM BONE-MARROW CULTURED-CELLS USING ADENOVIRAL VECTORS. Blood. A740-A740. 1994
- Trends in autologous hematopoietic stem cell transplant in older patients with Multiple Myeloma 2000-2017: The Canadian Experience
journal articles
- Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting. Clinical Lymphoma, Myeloma and Leukemia. 24:s215. 2024
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example. Oncology and Therapy. 12:239-245. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e227-e234. 2024
- Identification of cells of leukemic stem cell origin with non-canonical regenerative properties. Cell Reports Medicine. 5:101485-101485. 2024
- Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Transplantation and Cellular Therapy. 30:S187-S188. 2024
- Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. Transplantation and Cellular Therapy. 30:S189-S190. 2024
- LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism. Blood. 142:4156-4156. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Reports Medicine. 4:101108-101108. 2023
- Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Molecular Therapy - Methods and Clinical Development. 28:262-271. 2023
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. Blood. 140:8036-8037. 2022
- Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 6:4816-4820. 2022
- Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders. EMBO Molecular Medicine. 14:e14297. 2022
- An Overview of Modified Chitosan Adsorbents for the Removal of Precious Metals Species from Aqueous Media. Molecules. 27:978-978. 2022
- Automated bone marrow cytology using deep learning to generate a histogram of cell types. Communications Medicine. 2:45. 2022
- Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances. 5:4980-4991. 2021
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology. 22:1403-1415. 2021
- Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy. 23:820-832. 2021
- Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). Transplantation and Cellular Therapy. 27:S285-S285. 2021
- Lentivirus-mediated gene therapy for Fabry disease. Nature Communications. 12:1178. 2021
- Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. Cell Reports Medicine. 2:100202-100202. 2021
- Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. Current Oncology. 27:270-274. 2020
- Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations.. Current Oncology. 27:270-274. 2020
- Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 4:629-637. 2020
- Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances. 4:560-572. 2020
- Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology. 7:e100-e111. 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 11:93-99. 2020
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 380:45-56. 2019
- Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites. Current Oncology. 25:300-306. 2018
- Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell. 34:483-498.e5. 2018
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances. 2:1935-1945. 2018
- Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD. Blood. 131:2863-2866. 2018
- Forgiveness, spirituality and love: thematic analysis of last statements from Death Row, Texas (2002–17). QJM - Monthly Journal of the Association of Physicians. 111:399-403. 2018
- Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nature Cell Biology. 19:1336-1347. 2017
- CD56 ^bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 102:1936-1946. 2017
- How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey. Journal of Clinical Apheresis. 32:246-256. 2017
- The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Transfusion and Apheresis Science. 56:552-557. 2017
- Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology. 24:833-844.e9. 2017
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. Hematological Oncology. 35:27-27. 2017
- Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. Molecular Therapy - Methods and Clinical Development. 5:241-258. 2017
- Erratum to “Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study” [Biol Blood Marrow Transplant 2016;22:1410-1415]. Transplantation and Cellular Therapy. 23:534-534. 2017
- TTP: One of the TMA’s—How to sort it out. Transfusion and Apheresis Science. 56:57-58. 2017
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer immunology research. 4:881-892. 2016
- Transfusion‐related alloimmunization in children: epidemiology and effects of chemotherapy. Vox Sanguinis. 111:299-307. 2016
- Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. Transplantation and Cellular Therapy. 22:1410-1415. 2016
- Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. The Lancet Oncology. 17:164-173. 2016
- A phase‐II sequential case‐series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. British Journal of Haematology. 170:208-217. 2015
- Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells. 33:1839-1849. 2015
- Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS. Blood. 124:314-314. 2014
- Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Transplantation and Cellular Therapy. 20:1813-1818. 2014
- Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. Journal of Experimental Medicine (JEM). 211:1925-1935. 2014
- Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. World Journal of Stem Cells. 6:380-380. 2014
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. Frontiers in Immunology. 5:191. 2014
- A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. Blood. 122:709-709. 2013
- A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity. Science Translational Medicine. 5:205ra134. 2013
- Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. Journal of Clinical Oncology. 31:1164-1171. 2013
- Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Therapy. 20:24-34. 2013
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell. 149:1284-1297. 2012
- Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. International Immunology. 24:29-41. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 118:2091-2091. 2011
- Cellular magnetic resonance imaging of monocyte-derived dendritic cell migration from healthy donors and cancer patients as assessed in a scid mouse model. Cytotherapy. 13:1234-1248. 2011
- Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. International Journal of Oncology. 39:907-913. 2011
- Labelling dendritic cells with SPIO has implications for their subsequent in vivo migration as assessed with cellular MRI. Contrast Media and Molecular Imaging. 6:314-327. 2011
- Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group. Bone Marrow Transplantation. 45:1253-1255. 2010
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.. Blood. 114:1390-1390. 2009
- Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease.. Blood. 114:3576-3576. 2009
- Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease.. Blood. 114:3584-3584. 2009
- Characterizing Complex Polysera Produced by Antigen-Specific Immunization through the Use of Affinity-Selected Mimotopes. PLoS ONE. 4:e5309-e5309. 2009
- Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma. Blood. 112:4332-4332. 2008
- In Vitro Effects of Budesonide on Eosinophil-Basophil Lineage Commitment~!2008-03-03~!2008-05-27~!2008-06-13~!. Open Respiratory Medicine Journal. 2:60-66. 2008
- Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 27:208-217. 2008
- Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Frontiers in Bioscience - Landmark. Volume:3202-3202. 2008
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Transplantation and Cellular Therapy. 12:491-505. 2006
- Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate. Leukemia and Lymphoma. 47:297-306. 2006
- Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells. Hematology. 10:189-203. 2005
- Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection. Transfusion. 45:394-398. 2005
- Progenitor egress from the bone marrow after allergen challenge: Role of stromal cell–derived factor 1α and eotaxin. Journal of Allergy and Clinical Immunology. 115:501-507. 2005
- Bone Marrow‐Derived Dendritic Cell Vaccination of Dogs with Naturally Occurring Melanoma by Using Human gp100 Antigen. Journal of Veterinary Internal Medicine (JVIM). 19:56-63. 2005
- Bone Marrow–Derived Dendritic Cell Vaccination of Dogs with Naturally Occurring Melanoma by Using Human gp100 Antigen. Journal of Veterinary Internal Medicine (JVIM). 19:56-56. 2005
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells, Molecules, and Diseases. 33:222-226. 2004
- Kinetics of Bone Marrow Eosinophilopoiesis and Associated Cytokines after Allergen Inhalation. American Journal of Respiratory and Critical Care Medicine. 169:565-572. 2004
- Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. Blood. 103:93-99. 2004
- Allergen‐induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34⁺ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. Immunology. 109:536-546. 2003
- Budesonide enhancement of eosinophil differentiation in vitro does not involved IL-5Rα overexperesion or increased p38 MAP kinase activation. Journal of Allergy and Clinical Immunology. 111:S266-S266. 2003
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma. Leukemia and Lymphoma. 44:29-37. 2003
- Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets. Bone Marrow Transplantation. 30:851-860. 2002
- Allergen-induced Increases in Bone Marrow T Lymphocytes and Interleukin-5 Expression in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine. 166:883-889. 2002
- Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood. 100:869-878. 2002
- The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. Journal of Allergy and Clinical Immunology. 110:96-101. 2002
- Genetically modified dendritic cells in cancer therapy: Implications for transfusion medicine. Transfusion Medicine Reviews. 15:292-304. 2001
- Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy. The FASEB Journal. 15:1628-1630. 2001
- Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy.. The FASEB Journal. 15:1628-1630. 2001
- CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Therapy. 8:316-323. 2001
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. Blood. 96. 2000
- Characterization of Chemokine Receptors Expressed in Primitive Blood Cells During Human Hematopoietic Ontogeny. Stem Cells. 18:374-381. 2000
- Enhanced Immune Response to the Melanoma Antigen gp100 Using Recombinant Adenovirus-Transduced Dendritic Cells. Cellular Immunology. 198:131-138. 1999
- An Inhaled Corticosteroid, Budesonide, Reduces Baseline but Not Allergen-induced Increases in Bone Marrow Inflammatory Cell Progenitors in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 159:1457-1463. 1999
- An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine. 159:1457-1463. 1999
- Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression.. International Journal of Oncology. 14:771-776. 1999
- Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab. Current Oncology. 6:131-137. 1999
- Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplantation. 22:1199-1205. 1998
- . Transfusion Medicine Reviews. 12:303-304. 1998
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 12:1492-1493. 1998
- The Canadian Experience Using Plasma Exchange for Immune Thrombocytopenic Purpura. Transfusion and Apheresis Science. 19:295-300. 1998
- Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transplantation. 21:769-773. 1998
- Changes in Bone Marrow Inflammatory Cell Progenitors after Inhaled Allergen in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 157:99-105. 1998
- Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation.. Journal of Clinical Investigation. 100:2466-2475. 1997
- Transient Gene Transfer and Expression in the Lung. Chest. 111:89S-94S. 1997
- Intramarrow Cytokine Gene Transfer by Adenoviral Vectors in Dogs. Human Gene Therapy. 8:545-553. 1997
- Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung.. American Journal of Pathology. 149:1395-1403. 1996
- Recombinant Human Adenovirus with Rat MIP‐2 Gene Insertion Causes Prolonged PMN Recruitment to the Murine Brain. European Journal of Neuroscience. 8:1803-1811. 1996
- Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Journal of Leukocyte Biology. 59:481-488. 1996
- Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy. Rare Disease and Orphan Drugs Journal. 3:n/a-n/a.
preprints